STAT October 9, 2024
Katie Palmer

FDA’s Tala Fakhouri says the agency has so far received nearly 500 submissions with AI components

In the last year, pharma incumbents have leaned into partnerships with AI-driven startups to supercharge drug discovery efforts. High-powered models of protein structure and molecule binding can help identify new disease targets, and even help design new drugs. But AI-derived or not, a new drug candidate still has to wind its way through the painstaking clinical trial process. That is why the pharma industry is also leaning into AI as a tool to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Clinical Trials, FDA, Govt Agencies, Interview / Q&A, Technology, Trends
Related Articles:
FDA updates definition of 'healthy'
FDA Clears Withings’ New Blood Pressure Monitor That Allows Providers to Communicate Directly with Patients
4 takeaways from the FDA’s first digital health advisory committee
FDA commissioner, a veteran cardiologist, highlights ongoing issues with US healthcare system
FDA commissioner urges health systems to strengthen AI quality oversight

Share This Article